Patents by Inventor Bruce L. Geller

Bruce L. Geller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220135973
    Abstract: Provided are antisense oligomers targeted against bacterial mRNAs and other macromolecules associated with a biochemical pathway and/or cellular process, and related compositions and methods of using the oligomers and compositions to treat an infected mammalian subject, for example, as primary antimicrobials or as adjunctive therapies with classic antimicrobials.
    Type: Application
    Filed: October 12, 2021
    Publication date: May 5, 2022
    Applicants: Board of Regents, The University of Texas System, Oregon State University
    Inventors: David GREENBERG, Bruce L. GELLER
  • Patent number: 11293024
    Abstract: Provided are antisense oligonucleotides targeted against bacterial genes involved in biochemical pathways and/or cellular processes, and related compositions and methods of using the oligonucleotides and compositions, alone or in combination with other antimicrobial agents, for instance, in the treatment of an infected mammalian subject.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: April 5, 2022
    Assignees: Board of Regents, The University of Texas System, Oregon State University
    Inventors: Bruce L. Geller, David Greenberg
  • Patent number: 11142764
    Abstract: Provided are antisense oligomers targeted against bacterial mRNAs and other macromolecules associated with a biochemical pathway and/or cellular process, and related compositions and methods of using the oligomers and compositions to treat an infected mammalian subject, for example, as primary antimicrobials or as adjunctive therapies with classic antimicrobials.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: October 12, 2021
    Assignees: Board of Regents, The University of Texas System, Oregon State University
    Inventors: David Greenberg, Bruce L. Geller
  • Patent number: 11021706
    Abstract: Provided are antisense morpholino oligomers targeted against bacterial virulence factors such as genes that contribute to antibiotic resistance or biofilm formation, or genes associated with fatty acid biosynthesis, and related compositions and methods of using the oligomers and compositions, for instance, in the treatment of an infected mammalian subject.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: June 1, 2021
    Assignees: Board of Regents, The University of Texas System, Oregon State University
    Inventors: Bruce L. Geller, David Greenberg
  • Publication number: 20210155934
    Abstract: Provided are antisense morpholino oligomers targeted against bacterial virulence factors such as genes that contribute to antibiotic resistance or biofilm formation, or essential genes, and related compositions and methods of using the oligomers and compositions, for instance, in the treatment of an infected mammalian subject.
    Type: Application
    Filed: February 1, 2021
    Publication date: May 27, 2021
    Applicants: Board of Regents, The University of Texas System, Oregon State University
    Inventors: David GREENBERG, Bruce L. GELLER, Erdal TOPRAK
  • Patent number: 10907158
    Abstract: Provided are antisense morpholino oligomers targeted against bacterial virulence factors such as genes that contribute to antibiotic resistance or biofilm formation, or essential genes, and related compositions and methods of using the oligomers and compositions, for instance, in the treatment of an infected mammalian subject.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: February 2, 2021
    Assignees: Board of Regents, The University of Texas System, Oregon State University
    Inventors: David Greenberg, Bruce L. Geller, Erdal Toprak
  • Publication number: 20200283768
    Abstract: Provided are antisense oligomers targeted against bacterial mRNAs and other macromolecules associated with a biochemical pathway and/or cellular process, and related compositions and methods of using the oligomers and compositions to treat an infected mammalian subject, for example, as primary antimicrobials or as adjunctive therapies with classic antimicrobials.
    Type: Application
    Filed: October 19, 2018
    Publication date: September 10, 2020
    Applicants: Board of Regents, The University of Texas System, Oregon State University
    Inventors: Bruce L. GELLER, David GREENBERG
  • Publication number: 20200032254
    Abstract: Provided are antisense morpholino oligomers targeted against bacterial virulence factors such as genes that contribute to antibiotic resistance or biofilm formation, or genes associated with fatty acid biosynthesis, and related compositions and methods of using the oligomers and compositions, for instance, in the treatment of an infected mammalian subject.
    Type: Application
    Filed: September 1, 2017
    Publication date: January 30, 2020
    Inventors: Bruce L. Geller, David Greenberg
  • Patent number: 10391098
    Abstract: Provided are antisense oligomers targeted against or genes associated with a biochemical pathway and/or cellular process, and related compositions and methods of using the oligomers and compositions to treat an infected mammalian subject, for example, as primary antimicrobials or as adjunctive therapies with classic antimicrobials.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: August 27, 2019
    Assignees: Board of Regents, The University of Texas System, Oregon State University
    Inventors: Bruce L. Geller, David Greenberg
  • Publication number: 20190169609
    Abstract: Provided are antisense oligonucleotides targeted against bacterial genes involved in biochemical pathways and/or cellular processes, and related compositions and methods of using the oligonucleotides and compositions, alone or in combination with other antimicrobial agents, for instance, in the treatment of an infected mammalian subject.
    Type: Application
    Filed: December 23, 2015
    Publication date: June 6, 2019
    Inventors: Bruce L. Geller, David Greenberg
  • Publication number: 20190078095
    Abstract: Provided are antisense morpholino oligomers targeted against bacterial virulence factors such as genes that contribute to antibiotic resistance or biofilm formation, or essential genes, and related compositions and methods of using the oligomers and compositions, for instance, in the treatment of an infected mammalian subject.
    Type: Application
    Filed: December 22, 2016
    Publication date: March 14, 2019
    Applicants: Board of Regents, The University of Texas System, Oregon State University
    Inventors: David GREENBERG, Bruce L. GELLER, Erdal TOPRAK
  • Publication number: 20180362982
    Abstract: Provided are antisense oligomers targeted against bacterial mRNAs and other macromolecules associated with a biochemical pathway and/or cellular process, and related compositions and methods of using the oligomers and compositions to treat an infected mammalian subject, for example, as primary antimicrobials or as adjunctive therapies with classic antimicrobials.
    Type: Application
    Filed: December 22, 2016
    Publication date: December 20, 2018
    Applicants: Board of Regents, The University of Texas System, Oregon State University
    Inventors: David GREENBERG, Bruce L. GELLER
  • Patent number: 10144762
    Abstract: A method for enhancing, by at least 10 fold, the antibacterial activity of an antisense oligonucleotide composed of morpholino subunits linked by phosphorus-containing intersubunit linkages. The method includes one or both of: conjugating an arginine-rich carrier to a 3? or 5? end of the oligonucleotide and modifying the oligonucleotide to contain 20%-50% intersubunit linkages that are positively charged at physiological pH. Also disclosed is an antisense oligonucleotide having enhanced antibacterial activity by virtue of one or both modifications.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: December 4, 2018
    Assignee: SAREPTA THERAPEUTICS, INC.
    Inventors: Dwight D. Weller, Bruce L. Geller, Patrick L. Iversen, Lucas D. Tilley, Jed N. Hassinger
  • Patent number: 9790495
    Abstract: Provided are antisense morpholino oligomers targeted against bacterial virulence factors such as genes that contribute to antibiotic resistance or biofilm formation, or genes associated with fatty acid biosynthesis, and related compositions and methods of using the oligomers and compositions, for instance, in the treatment of an infected mammalian subject.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: October 17, 2017
    Assignees: Oregon State University, Board of Regents, The University of Texas System
    Inventors: Bruce L. Geller, David Greenberg
  • Publication number: 20170247410
    Abstract: A method for enhancing, by at least 10 fold, the antibacterial activity of an antisense oligonucleotide composed of morpholino subunits linked by phosphorus-containing intersubunit linkages. The method includes one or both of: conjugating an arginine-rich carrier to a 3? or 5? end of the oligonucleotide and modifying the oligonucleotide to contain 20%-50% intersubunit linkages that are positively charged at physiological pH. Also disclosed is an antisense oligonucleotide having enhanced antibacterial activity by virtue of one or both modifications.
    Type: Application
    Filed: October 14, 2016
    Publication date: August 31, 2017
    Inventors: Dwight D. Weller, Bruce L. Geller, Patrick L. Iversen, Lucas D. Tilley, Jed N. Hassinger
  • Patent number: 9534220
    Abstract: A method and antisense compound for inhibiting the growth of pathogenic bacterial cells are disclosed. The compound contains no more than 12 nucleotide bases and has a targeting nucleic acid sequence of no fewer than 10 bases in length that is complementary to a target sequence containing or within 10 bases, in a downstream direction, of the translational start codon of a bacterial mRNA that encodes a bacterial protein essential for bacterial replication. The compound binds to a target mRNA with a Tm of between 50° to 60° C. The relatively short antisense compounds are substantially more active than conventional antisense compounds having a targeting base sequence of 15 or more bases.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: January 3, 2017
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Bruce L. Geller, Jesse D. Deere, Patrick L. Iversen
  • Patent number: 9499583
    Abstract: A method for enhancing, by at least 10 fold, the antibacterial activity of an antisense oligonucleotide composed of morpholino subunits linked by phosphorus-containing intersubunit linkages. The method includes one or both of: conjugating an arginine-rich carrier to a 3? or 5? end of the oligonucleotide and modifying the oligonucleotide to contain 20%-50% intersubunit linkages that are positively charged at physiological pH. Also disclosed is an antisense oligonucleotide having enhanced antibacterial activity by virtue of one or both modifications.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: November 22, 2016
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Dwight D. Weller, Bruce L. Geller, Patrick L. Iversen, Lucas D. Tilley, Jed N. Hassinger
  • Patent number: 9487784
    Abstract: A method and antisense compound for inhibiting the growth of pathogenic bacterial cells are disclosed. The compound contains no more than 12 nucleotide bases and has a targeting nucleic acid sequence of no fewer than 10 bases in length that is complementary to a target sequence containing or within 10 bases, in a downstream direction, of the translational start codon of a bacterial mRNA that encodes a bacterial protein essential for bacterial replication. The compound binds to a target mRNA with a Tm of between 50° to 60° C. The relatively short antisense compounds are substantially more active than conventional antisense compounds having a targeting base sequence of 15 or more bases.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: November 8, 2016
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Bruce L. Geller, Jesse D. Deere, Patrick L. Iversen
  • Publication number: 20160251398
    Abstract: A method for enhancing, by at least 10 fold, the antibacterial activity of an antisense oligonucleotide composed of morpholino subunits linked by phosphorus-containing intersubunit linkages. The method includes one or both of: conjugating an arginine-rich carrier to a 3? or 5? end of the oligonucleotide and modifying the oligonucleotide to contain 20%-50% intersubunit linkages that are positively charged at physiological pH. Also disclosed is an antisense oligonucleotide having enhanced antibacterial activity by virtue of one or both modifications.
    Type: Application
    Filed: December 21, 2015
    Publication date: September 1, 2016
    Inventors: Dwight D. Weller, Bruce L. Geller, Patrick L. Iversen, Lucas D. Tilley, Jed N. Hassinger
  • Publication number: 20160106857
    Abstract: Provided are antisense oligomers targeted against or genes associated with a biochemical pathway and/or cellular process, and related compositions and methods of using the oligomers and compositions to treat an infected mammalian subject, for example, as primary antimicrobials or as adjunctive therapies with classic antimicrobials.
    Type: Application
    Filed: May 15, 2015
    Publication date: April 21, 2016
    Inventors: Bruce L. Geller, David Greenberg